REVIEW Cilnidipine is a dihydropyridine dual-type calcium channel blocker. It blocks L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels.
Hirose, Takeshi; Suzuki, Hidehiko Cilnidipine for treatment of heart diseases Jpn. Kokai Tokkyo Koho (2000), JP 2000309535 A 20001107.
L?hn M, Muzzulini U, Essin K, Tsang SY, Kirsch T, Litteral J, Waldron P, Conrad H, Klugbauer N, Hofmann F, Haller H, Luft FC, Huang Y, Gollasch M Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J Hypertens. 2002 May;20(5):885-93.
Yamamoto Takashi; Niwa Seiji; Ohno Seiji; Onishi Tomoyuki; Matsueda Hiroyuki; Koganei Hajime; Uneyama Hisayuki; Fujita Shin-ichi; Takeda Tomoko; Kito Morikazu; et al Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels Bioorganic & medicinal chemistry letters (2006), 16(4), 798-802.
Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, Shoji S, Koyama H, Shoji T, Emoto M, Nishizawa Y, Inaba M; Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (CLEARED) Study Investigators (2012). Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res Clin Pract. 97(1):91-8. PMID 22336632.
For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.